Monthly Archives: October 2022

DC ineligibility findings for computer-related claims affirmed-in-part and reversed-in part as some showed improvement of “a problem unique to the Internet”

Posted on October 25, 2022 by Patrick J. Halloran, Ph.D., J.D.

Shalon Weisner and Shmuel Nemanov v. Google LLC Docket No. 2021-2228 (IPR2020-00040) (https://cafc.uscourts.gov/opinions-orders/21-2228.OPINION.10-13-2022_2017814.pdf) REYNA, HUGHES, STOLL October 13, 2022 Brief Summary:   DC decisions on patent ineligibility claims affirmed-in-part and reversed-in-part as two of the patents arguably “recite a specific … Continue reading →

Posted in Patent Eligibility (101), Section 101 (see also Patentability), Software | Leave a comment

IPR finding that Mylan did not show Merck’s DP-IV claims invalid for anticipation or obviousness affirmed

Posted on October 3, 2022 by Patrick J. Halloran, Ph.D., J.D.

Mylan Pharmaceuticals Inc. v. Merck Sharp & Dome Corp. Docket No. 2021-2121 (IPR2020-00040) (https://cafc.uscourts.gov/opinions-orders/21-2121.OPINION.9-29-2022_2010851.pdf) LOURIE, REYNA, STOLL September 29, 2022 Brief Summary:   Board IPR finding that Mylan did not show Merck’s DP-IV claims invalid for anticipation or obviousness affirmed. … Continue reading →

Posted in Anticipation (35 USC 102), Conception and Reduction to Practice, Generics / ANDA, Inherency, Inter Parties Review (IPR), IPR, Obviousness, Obviousness (Secondary Considerations) | Leave a comment